CABA Stock Overview
A clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Cabaletta Bio, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$11.81 |
52 Week High | US$26.35 |
52 Week Low | US$9.02 |
Beta | 2.52 |
1 Month Change | -11.34% |
3 Month Change | -46.78% |
1 Year Change | 15.00% |
3 Year Change | 3.96% |
5 Year Change | n/a |
Change since IPO | 18.10% |
Recent News & Updates
Recent updates
Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans
May 22Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward
Jan 31Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans
Dec 28Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation
Sep 12Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation
Jun 04Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans
Feb 11We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully
Oct 20We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully
Jul 07Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans
Mar 24We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely
Dec 09We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate
Aug 05Cabaletta Bio EPS beats by $0.08
May 03Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans
Apr 12What Percentage Of Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Do Insiders Own?
Feb 19Chardan Capital initiates Cabaletta Bio with Buy rating
Jan 08We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely
Dec 28Dosing underway in Cabaletta Bio's DSG3-CAART study in a rare skin blistering disorder
Dec 09Cabaletta Bio +5% on Q3 results, pipeline update
Nov 10Shareholder Returns
CABA | US Biotechs | US Market | |
---|---|---|---|
7D | -6.9% | 0.7% | 1.2% |
1Y | 15.0% | 5.0% | 27.7% |
Return vs Industry: CABA exceeded the US Biotechs industry which returned 5% over the past year.
Return vs Market: CABA underperformed the US Market which returned 27.7% over the past year.
Price Volatility
CABA volatility | |
---|---|
CABA Average Weekly Movement | 10.6% |
Biotechs Industry Average Movement | 11.2% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 16.2% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: CABA's share price has been volatile over the past 3 months.
Volatility Over Time: CABA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2017 | 119 | Steven Nichtberger | www.cabalettabio.com |
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company’s lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis.
Cabaletta Bio, Inc. Fundamentals Summary
CABA fundamental statistics | |
---|---|
Market cap | US$588.49m |
Earnings (TTM) | -US$76.87m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.4x
P/E RatioIs CABA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CABA income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$76.87m |
Earnings | -US$76.87m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.59 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did CABA perform over the long term?
See historical performance and comparison